Begin main content

Reports

We found 6186 result(s)

2019 CADTH Symposium

Event Date: April 14, 2019 - April 16, 2019
Result type: Events

CADTH will be hosting its annual Symposium at the Shaw Centre in Edmonton, Alberta, from April 14 to 16, 2019. For more information, please visit the CADTH Symposium website. Questions may be sent by email to symposium@cadth.ca.

apomorphine hydrochloride (Kynmobi)

Last Updated: March 19, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: apomorphine hydrochloride
Indications: Parkinson’s Disease

  • Brand Name: Kynmobi
  • Manufacturer: Sunovion Pharmaceuticals Canada Inc.
  • Project Number: SR0604-000
  • Project Status: Active
  • Submission Type: New

Tags

Nervous System, Nervous system, Parkinson

dolutegravir / lamivudine (TBC)

Last Updated: March 19, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: dolutegravir / lamivudine
Indications: HIV-1 infection

  • Brand Name: TBC
  • Manufacturer: ViiV Healthcare
  • Project Number: SR0601-000
  • Project Status: Active
  • Submission Type: New

Tags

Infectious Diseases, Pediatrics, HIV/AIDS, Infectious diseases, Pediatrics

Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration

Published on: March 19, 2019
Result type: Reports
Product Line: Optimal Use

This project will assess the clinical and economic effectiveness of extending dual antiplatelet therapy (i.e., the combination of ASA and a P2Y12 inhibitor) following percutaneous coronary intervention; findings will be summarized in a Science Report. This report will aim to answer the following policy questions: Is it cost-effective to extend t...

  • Project Number: OP0533-000

Tags

Angioplasty, Aspirin, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists, Stents, Cardiovascular, Surgery, Balloon, Brilinta, Brilique, DAPT, DES, Effient, Laser-Assisted, PCI, Percutaneous Coronary Intervention, Plavix, Stent, Stenting, angioplasties, prasugrel, ticagrelor

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Published on: March 19, 2019
Result type: Reports
Product Line: Optimal Use
Research Type: Device

Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological and/or psychological intervent...

  • Project Number: OP0534-000

Tags

Anxiety Disorders, Depression, Mental Health, Anxiety disorders, Depression, Dépression, Mental health

inotersen (Tegsedi)

Last Updated: March 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: inotersen
Indications: hereditary transthyretin amyloidosis

  • Brand Name: Tegsedi
  • Manufacturer: Akcea Therapeutics Inc.
  • Project Number: SR0603-000
  • Project Status: Active
  • Submission Type: New

Tags

Genetics, Nervous System, Genetics, Nervous system

efinaconazole (Jublia)

Last Updated: December 18, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: efinaconazole
Indications: Onychomycosis

  • Brand Name: Jublia
  • Manufacturer: Valeant Canada LP
  • Project Number: SR0577-000
  • Project Status: Active
  • Submission Type: New

Tags

Dermatology, Dermatology

Latanoprostene bunod (Vyzulta )

Last Updated: December 20, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: latanoprostene bunod
Indications: Open-angle glaucoma or ocular hypertension

  • Brand Name: Vyzulta
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0590-000
  • Project Status: Active
  • Submission Type: New

Tags

Eye, Glaucoma, Open-Angle, Intraocular Pressure, Ocular Hypertension, Ophthalmic Solutions, latanoprostene bunod; ocular hypertension; open-angle glaucoma; intraocular pressure

insulin glargine (Semglee)

Last Updated: March 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: insulin glargine
Indications: Diabetes mellitus, Type 1 & 2

  • Brand Name: Semglee
  • Manufacturer: BGP PHARMA ULC
  • Project Number: SE0589-000
  • Project Status: Withdrawn
  • Submission Type: New

Tags

Pediatrics, Diabetes, Pediatrics

Intranasal Corticosteroids for the Management of Chronic Rhinosinusitis or Nasal Polyposis in Cystic Fibrosis: A Review of Clinical Effectiveness

Published on: March 18, 2019
Result type: Reports
Product Line: Rapid Response
Research Type: Drug

  • Project Number: RC1083-000

Tags

Cystic Fibrosis, Administration, Intranasal, Adrenal Cortex Hormones, Beclomethasone, Budesonide, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Fluocinolone Acetonide, Glucocorticoids, Inhalation, Nasal Sprays, Pregnenediones, Triamcinolone, Cystic Fibrosis, Medical devices, Cystic Fibrosis, intranasal, Corticosteroid, Corticosteroids, Cystic Fibrosis, nasal spray, nasal delivery